

Blue Cross and BCN to use Audaire Health™ provider portal to capture clinical outcomes for CAR-T cell therapy drugs

Starting July 1, 2023, Blue Cross Blue Shield of Michigan and Blue Care Network will start using the Audaire Health provider portal to track and capture clinical outcomes for CAR-T cell therapy drugs for Blue Cross commercial and BCN commercial members.

The data providers enter in the Audaire provider portal will enable Blue Cross and BCN to capture and assess the clinical benefit of these therapies.

Note: This process will replace the manual reporting process for clinical outcomes for CAR-T cell therapy drugs, thereby reducing administrative burden. Blue Cross or BCN will no longer fax forms to prescribing providers on an annual basis for them to enter clinical outcome information and send back to us.

Which CAR-T cell therapy drugs are affected?

Starting July 1, Blue Cross and BCN will require providers to enter clinical outcomes into the Audaire provider portal for the following CAR-T cell therapies, which are covered under members' medical benefits.

HCPCS code	Brand name	Generic name
Q2055	Abecma®	idecabtagene vicleucel
Q2054	Breyanzi®	lisocabtagene maraleucel
Q2056	Carvykti™	ciltacabtagene autoleucel
Q2042	Kymriah®	tisagenlecleucel
Q2053	Tecartus®	brexucabtagene autoleucel
Q2041	Yescarta®	axicabtagene ciloleucel

Notes:

- Current requirements will continue to apply to these drugs. Continue to submit prior authorization requests through the NovoLogix® online tool. (To access NovoLogix, log in to our provider portal (availity.com*), click on *Payer Spaces* and then click on the BCBSM and BCN logo; this will take you to the Blue Cross and BCN payer space, where you'll find links to the NovoLogix tools on the *Applications* tab. If you don't have access to Availity®, see the [Register for web tools](#) page on bcbsm.com.)

- We'll require that providers enter clinical information in the Audaire provider portal for any CAR-T cell therapy drugs that are approved by the Food and Drug Administration, or FDA, after July 1, 2023.

What will change on July 1?

- The first time Blue Cross or BCN approves a prior authorization request you submitted for one of these therapies, you (the requesting provider) must attest that you'll enter clinical outcome information in the Audaire provider portal as requested by Blue Cross or BCN. Attestation is required for the therapies to be covered by a member's benefit. (See [How should you prepare for this change?](#) below to learn more about attestation.)
- For any member who is approved for one of these therapies, we'll automatically add their basic information to the Audaire provider portal.

Note: We'll also add basic information for any members who were approved for one of these therapies from Jan. 1, 2022, through June 30, 2023. An Audaire representative will reach out to ask that the requesting provider enter clinical outcome information in the Audaire provider portal for these members.

- Providers or their offices will receive email reminders from Audaire on a regular basis to remind them to submit clinical information. The email messages will be sent by **hello@audaire.com**, and they'll include a direct link to the portal for easy access.

Providers can use either of these submission methods:

- Entering clinical information in the easy-to-use survey format in the Audaire provider portal.
- Calling 512-643-5099. After stating your name, you'll be connected to an Audaire representative, who can enter the clinical information on your behalf.

Note: To get help entering information in the Audaire provider portal, call 512-643-5099 to schedule an appointment with an Audaire representative.

How should you prepare for this change?

You don't need to take action.

The first time Blue Cross or BCN approves a prior authorization request you submitted for one of these therapies, an Audaire representative will reach out to you to set up a 30-minute phone call during which they'll:

- Create your Audaire Health profile, which will complete your attestation
- Provide training on how to use the Audaire provider portal

- Answer your questions about the Audaire provider portal

Note: An Audaire representative will also reach out to you if you have patients for whom we approved an authorization request for one of these therapies prior to July 1 and who have active coverage with Blue Cross or BCN.

Why are we making this change?

CAR-T cell therapies are high-cost treatments, and Blue Cross and BCN recognize the value and therapeutic promise these therapies hold. The goal of collecting this data is to ensure member access to therapies while maintaining affordability.

Do any other drugs require tracking in the Audaire provider portal?

Blue Cross and BCN also require providers to track clinical outcomes for commercial members for the following high-cost spinal muscular atrophy therapies: Zolgensma[®] (onasemnogene abeparvovec-xioi), Spinraza[®] (nusinersen) and Evrysdi[®] (risdiplam). For additional details, see the [October 2022 Record](#) article and the [November-December 2022 BCN Provider News](#) article.

Questions?

If you have questions about this change, send them to Allison Olmsted, Pharm.D., at aolmsted@bcbsm.com.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Audaire Health is a contracted vendor that provides select services to Blue Cross and BCN commercial members.

Availity[®] is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.